Market Overview

Report: AstraZeneca Eyes Acquisition Of Relypsa For $46 Per Share


Shares of Relypsa Inc (NASDAQ: RLYP) were trading higher by more than 2 percent at $28.60 early Thursday morning after the Daily Mail reported the company may be a potential acquisition target.

The Daily Mail reported that "rumors from across the Pond" suggest that AstraZeneca plc (ADR) (NYSE: AZN) is eyeing another acquisition just weeks after acquiring ZS Pharma. The publication suggested that the company's CEO Pascal Soriot "now wants to take out" Relypsa –- ZS Pharma's biggest competitor.

Posted-In: AstraZeneca Daily Mail Pascal Soriot Pharmaceutical M&A RelypsaM&A News Rumors


Related Articles (AZN + RLYP)

View Comments and Join the Discussion!
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at